Fresh analysis indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional diet and exercise plans.
Published data in a leading medical journal shows that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying these treatments should be informed of the risk of rapid rebound weight gain when the therapy is stopped," stated expert Dr. Susan Jebb.
This pace of regain means a return to starting weight within about one and a half years.
Weighing Approaches
The analysis, which looked at 37 of studies involving thousands of participants, contrasted the outcomes of these new drugs with other pills.
The team emphasize that people who shed pounds through diet and exercise generally see a less rapid weight regain—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Nutrition scientists suggest the mode of action of the jabs is key to understanding the heightened weight return.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating far more likely."
An Ongoing Condition?
Health authorities suggest the injections for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, given the high risk of relapse, the therapy might need to be long-term.
This opinion is supported by drug manufacturers, who say that the results "highlight the long-term character of obesity," similar to managing diseases like hypertension.
Patient Testimonies
Users who have discontinued the medication describe a powerful return of hunger.
"I experienced something activating and you become ravenous," recalled one woman.
This challenge is worsened if individuals have not established permanent dietary or behavioural modifications during therapy.
Growing Use
Survey data suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is higher among females than males.
- The middle-aged age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Ultimately, experts emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and long-term success relies on ongoing lifestyle management.
